Bain Capital Life Sciences Investors, LLC

Person Signing this Report on Behalf of Reporting Manager:

Bain Capital Life Sciences Investors, LLC is (i) the general partner of Bain Capital Life Sciences Partners, LP, which is the general partner of Bain Capital Life Sciences Fund, L.P., (ii) the general partner of BC SW, LP, (iii) the manager of Bain Capital Life Sciences Investors II, LLC, which is the general partner of Bain Capital Life Sciences Fund II, L.P., which is the manager of BCLS II Investco (GP), LLC, which is the general partner of BCLS II Investco, LP, and (iv) the manager of Bain Capital Life Sciences III General Partner, LLC, which is the general partner of Bain Capital Life Sciences Fund III, L.P., which is the sole member of Bain Capital Life Sciences Opportunities III GP, LLC, which is the general partner of Bain Capital Life Sciences Opportunities III, LP. The shares of Disc Medicine, Inc. ("IRON") reflect the exercise of securities held by Bain Capital Life Sciences Opportunities III, LP for IRON common stock. As of 6/30/23, such person held 103,324 shares of IRON common stock. The shares of Savara Inc. ("SVRA") are as reported on Amendment No. 1 to the Schedule 13D filed by Bain Capital Life Sciences Fund II, L.P. and BCIP Life Sciences Associates, LP on 3/17/21 and reflect the exercise of securities held by such persons for SVRA common stock, after giving effect to provisions that prevent exercise if such persons would beneficially own more than 9.99% of the SVRA common stock following such exercise. As of 6/30/23, such persons held 6,913,208 shares of SVRA common stock. The shares of Syros Pharmaceuticals, Inc. ("SYRS") are as reported on Amendment No. 2 to the Schedule 13G filed by Bain Capital Life Sciences Fund II, L.P., BCIP Life Sciences Associates, LP and BCLS II Equity Opportunities, LP on 2/14/23 and reflect the exercise of securities held by such persons for SYRS common stock, after giving effect to provisions that prevent exercise if such persons would beneficially own more than 9.99% of the SYRS common stock following such exercise. As of 6/30/23, such persons held 1,082,404 shares of SYRS common stock. The shares of X4 Pharmaceuticals, Inc. ("XFOR") reflect the exercise of securities held by Bain Capital Life Sciences Fund, L.P., Bain Capital Life Sciences Fund II, L.P., BCIP Life Sciences Associates, LP, BCLS II Investco, LP and BCLS I Investco, LP for XFOR common stock, after giving effect to provisions the prevent exercise if such persons would beneficially own more than 9.99% of the XFOR common stock following such exercise. As of 6/30/23, such persons held 14,879,809 shares of XFOR common stock.

Other Included Managers (11):